The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function

Biochemical Journal

Volumn 450, Issue 1, 2013, Pages 169-178

  Coothankandaswamy, Veena ^a   Elangovan, Selvakumar ^a   Singh, Nagendra ^a   Prasad, Puttur D ^a   Thangaraju, Muthusamy ^a   Ganapathy, Vadivel ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Histone deacetylase (HDAC); Member 8 (SLC5A8); Signal transducer and activator of transcription 3 (STAT3); Solute carrier gene family 5A; Survivin; Tumour suppressor

Indexed keywords

CASPASE 3; HISTONE; HISTONE DEACETYLASE; PYRUVIC ACID; SEROTONIN TRANSPORTER; SLC5A8 PROTEIN; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL LEVEL; CELL MEMBRANE; CELL NUCLEUS; CHEMOSENSITIVITY; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MITOSIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TRANSCRIPTION TERMINATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84873048782     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121248     Document Type: Article

References (32)

1. Ganapathy, V., Gopal, E., Miyauchi, S. and Prasad, P. D. (2005) Biological functions of SLC5A8, a candidate tumor suppressor. Biochem. Soc. Trans. 33, 237-240
2. Gupta, N., Martin, P. M., Prasad, P. D. and Ganapathy, V. (2006) SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 78, 2419-2425
3. Ganapathy, V., Thangaraju, M., Gopal, E., Itagaki, S., Miyauchi, S. and Prasad, P. D. (2008) Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 10, 193-199
4. Ganapathy, V., Thangaraju, M. and Prasad, P. D. (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 121, 29-40
5. Li, H., Myeroff, L., Smiraglia, D., Romero, M. F., Pretlow, T. P., Kasturi, L., Lutterbaugh, J., Rerko, R. M., Casey, G., Issa, J. P. et al. (2003) SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc. Natl. Acad. Sci. U.S.A. 100, 8412-8417
6. +-coupled transporter for short-chain fatty acids. J. Biol. Chem. 279, 13293-13296
7. +-monocarboxylate cotransporter. J. Physiol. 557, 719-731
8. Davie, J. R. (2003) Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133, 2485S-2493S
9. Cresci, G. A., Thangaraju, M., Mellinger, J. D., Liu, K. and Ganapathy, V. (2010) Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J. Gastrointest. Surg. 14, 449-461
10. Thangaraju, M., Carswell, K. N., Prasad, P. D. and Ganapathy, V. (2009) Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem. J. 417, 379-389
11. Thangaraju, M., Cresci, G., Itagaki, S., Mellinger, J., Browning, D. D., Berger, F. G., Prasad, P. D. and Ganapathy, V. (2008) Sodium-coupled transport of the short-chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J. Gastrointest. Surg. 12, 1773-1782
12. Thangaraju, M., Gopal, E., Martin, P. M., Ananth, S., Smith, S. B., Prasad, P. D., Sterneck, E. and Ganapathy, V. (2006) SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 66, 11560-11564
13. +/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc. Natl. Acad. Sci. U.S.A. 103, 7270-7275
14. Bennett, K. L., Romigh, T. and Eng, C. (2009) Disruption of transforming growth factor-β signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. Cancer Res. 69, 9301-9305
15. Deveraux, Q. L. and Reed, J. C. (1999) IAP family proteins-suppressors of apoptosis. Genes Dev. 13, 239-252
16. Mita, A. C., Mita, M. M., Nawrocki, S. T. and Giles, F. J. (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 14, 5000-5005
17. Rödel, F., Reichert, S., Sprenger, T., Gaipl, U. S. and Mirsch, J. (2011) The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr. Med. Chem. 18, 191-199
18. Musacchio, A. (2010) Molecular biology. Surfing chromosomes (and Survivin). Science 330, 183-184
19. Ruchaud, S., Carmena, M. and Earnshaw, W. C. (2007) Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 8, 798-812
20. Park, J. Y., Helm, J. F., Zheng, W., Ly, Q. P., Hodul, P. J., Centeno, B. A. and Malafa, M. P. (2008) Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas 36, e32-e39
21. 0, +), a highly concentrative and broad-specific amino acid transporter, is a novel and effective target for treatment of estrogen receptor-positive breast cancer. J. Biol. Chem. 286, 31380-31388
22. Elangovan, S., Ramachandran, S., Venkatesan, N., Ananth, S., Gnana-Prakasam, J. P., Martin, P. M., Browning, D. D., Schoenlein, P. V., Prasad, P. D., Ganapathy, V. and Thangaraju, M. (2011) SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res. 71, 6654-6664
23. Zhang, M., Yang, J. and Li, F. (2006) Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J. Exp. Clin. Cancer Res. 25, 391-402
24. Chowdhury, S., Howell, G. M., Teggart, C. A., Chowdhury, A., Person, J. J., Bowers, D. M. and Brattain, M. G. (2011) Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor β (TGFβ) receptor II leading to cancer cell death. J. Biol. Chem. 286, 30937-30948
25. Cheung, C. H., Cheng, L., Chang, K. Y., Chen, H. H. and Chang, J. Y. (2011) Investigations of survivin: the past, present and future. Front. Biosci. 16, 952-961
26. Yang, D., Welm, A. and Bishop, J. M. (2004) Cell division and cell survival in the absence of survivin. Proc. Natl. Acad. Sci. U.S.A. 101, 15100-15105
27. Chen, J., Jin, S., Tahir, S. K., Zhang, H., Liu, X., Sarthy, A. V., McGonigal, T. P., Liu, Z., Rosenberg, S. H. and Ng, S. C. (2003) Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J. Biol. Chem. 278, 486-490
28. Schimmer, A. D. (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 64, 7183-7190
29. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320
30. Liu, T., Brouha, B. and Grossman, D. (2004) Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells. Oncogene 23, 39-48
31. Altieri, D. C. (2003) Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54
32. Kanwar, J. R., Kamalapuram, S. K. and Kanwar, R. K. (2011) Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today 16, 485-494